Keyphrases
Panitumumab
100%
Missense mutation
100%
Therapeutic Response
100%
Metastatic Colorectal Cancer (mCRC)
100%
Combination Chemotherapy
100%
Epidermal Growth Factor Receptor Inhibitors
100%
Tumor
50%
Epidermal Growth Factor Receptor
50%
Monoclonal Antibody
25%
Chemotherapy
25%
Biomarker Response
25%
Cetuximab
25%
Clinical Laboratory
25%
KRAS mutation
25%
Receptor Targets
25%
Retrospective Clinical Study
25%
Radiological Response
25%
Low Prevalence
25%
Subset Analysis
25%
Codon 12
25%
Carcinoembryonic Antigen
25%
KRAS mutant
25%
Prospective Clinical Study
25%
KRAS Oncogene
25%
Ras Family
25%
Family Gene
25%
Generalized Approach
25%
RECIST 1.1
25%
FOLFIRI
25%
Equivalent Resistance
25%
Expert Consensus Guidelines
25%
Medicine and Dentistry
Metastatic Colorectal Cancer
100%
Treatment Response
100%
Missense Mutation
100%
Combination Chemotherapy
100%
Epidermal Growth Factor Receptor
100%
Epidermal Growth Factor Receptor Kinase Inhibitor
100%
Panitumumab
100%
Neoplasm
66%
Biological Marker
33%
Chemotherapy
33%
Clinical Study
33%
Prevalence
33%
Oncogene
33%
Metastatic Colon Cancer
33%
Multigene Family
33%
FOLFIRI
33%
Monoclonal Antibody
33%
Carcinoembryonic Antigen
33%
Codon
33%
Cetuximab
33%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Metastatic Colorectal Cancer
100%
Epidermal Growth Factor Receptor Kinase Inhibitor
100%
Epidermal Growth Factor Receptor
100%
Panitumumab
100%
Neoplasm
66%
Clinical Study
33%
Biological Marker
33%
Prevalence
33%
Metastatic Colon Cancer
33%
Monoclonal Antibody
33%
Carcinoembryonic Antigen
33%
Cetuximab
33%
Biochemistry, Genetics and Molecular Biology
KRAS
100%
Missense Mutation
100%
Growth Factor Receptor Inhibitor
100%
Epidermal Growth Factor Receptor
100%
Panitumumab
100%
Oncogene
16%
Clinical Study
16%
Colon
16%
Multigene Family
16%
Prevalence
16%
Codon
16%
Monoclonal Antibody
16%
Carcinoembryonic Antigen
16%
Cetuximab
16%
Neuroscience
Growth Factor Receptor Inhibitor
100%
Missense Mutation
100%
Panitumumab
100%
Epidermal Growth Factor Receptor
100%
Monoclonal Antibody
16%
Carcinoembryonic Antigen
16%
Cetuximab
16%
Oncogene
16%
Multigene Family
16%
Codon
16%
FOLFIRI
16%